Published in Springerplus on September 09, 2016
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature (2014) 4.95
CRISPR RNA-guided activation of endogenous human genes. Nat Methods (2013) 4.69
Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell (2013) 4.05
Poly(ethylenimine) and its role in gene delivery. J Control Release (1999) 3.78
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res (2013) 3.50
Current status of polymeric gene delivery systems. Adv Drug Deliv Rev (2006) 3.04
Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm (2005) 2.88
A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res (2008) 2.63
Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun (2015) 2.56
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev (2002) 2.27
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports (2014) 1.88
Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol (2009) 1.77
Barriers to nonviral gene delivery. J Pharm Sci (2003) 1.77
The CRISPR craze. Science (2013) 1.63
Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev (2005) 1.49
Quantitative study of electroporation-mediated molecular uptake and cell viability. Biophys J (2001) 1.37
Efficient generation of knock-in transgenic zebrafish carrying reporter/driver genes by CRISPR/Cas9-mediated genome engineering. Sci Rep (2014) 1.36
A review of gene and stem cell therapy in cutaneous wound healing. Burns (2008) 1.34
Cell wound repair in Drosophila occurs through three distinct phases of membrane and cytoskeletal remodeling. J Cell Biol (2011) 1.34
Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system. Int J Mol Sci (2013) 1.34
Key issues in non-viral gene delivery. Adv Drug Deliv Rev (2001) 1.32
Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia (2003) 1.21
Adeno-associated virus vector integration. Curr Opin Mol Ther (2009) 1.20
Vectors and delivery systems in gene therapy. Med Sci Monit (2005) 1.19
Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev (2002) 1.17
How to screen non-viral gene delivery systems in vitro? J Control Release (2011) 1.17
Physical non-viral gene delivery methods for tissue engineering. Ann Biomed Eng (2012) 1.06
Lentiviral gene transfer of SDF-1alpha to wounds improves diabetic wound healing. J Surg Res (2007) 1.06
In vivo gene transfer to skin and wound by microseeding. J Surg Res (1998) 1.05
Recent progress in gene delivery using non-viral transfer complexes. J Control Release (2001) 1.00
Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs (2002) 0.99
Efficient production of mice from embryonic stem cells injected into four- or eight-cell embryos by piezo micromanipulation. Stem Cells (2008) 0.98
Recent development of nonviral gene delivery systems with virus-like structures and mechanisms. Eur J Pharm Biopharm (2008) 0.98
Immune responses to lentiviral vectors. Curr Gene Ther (2007) 0.97
Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci Rep (2014) 0.96
The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem (2006) 0.95
The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals. Transgenic Res (2014) 0.95
E-cadherin promotes incorporation of mouse epiblast stem cells into normal development. PLoS One (2012) 0.94
Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials (2009) 0.93
Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice--implications for the use of genetically modified keratinocytes to modulate dermal regeneration. J Invest Dermatol (1995) 0.93
Molecular scissors and their application in genetically modified farm animals. Transgenic Res (2015) 0.92
Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol (2008) 0.91
Single cell wound repair: Dealing with life's little traumas. Bioarchitecture (2011) 0.90
Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med (2015) 0.89
Non-viral gene transfection technologies for genetic engineering of stem cells. Eur J Pharm Biopharm (2007) 0.88
Calcium condensation of DNA complexed with cell-penetrating peptides offers efficient, noncytotoxic gene delivery. J Pharm Sci (2010) 0.87
Analysis of cationic-lipid-plasmid-DNA complexes. Anal Chem (2007) 0.86
Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. Int J Pharm (2011) 0.85
Efficient production of chimeric mice from embryonic stem cells injected into 4- to 8-cell and blastocyst embryos. J Anim Sci Biotechnol (2013) 0.83
CRISPR/Cas9-mediated reporter knock-in in mouse haploid embryonic stem cells. Sci Rep (2015) 0.83
Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. J Pharm Sci (2010) 0.82
The potential of the combination of CRISPR/Cas9 and pluripotent stem cells to provide human organs from chimaeric pigs. Int J Mol Sci (2015) 0.82
Successful reprogramming of epiblast stem cells by blocking nuclear localization of β-catenin. Stem Cell Reports (2014) 0.81
Stem cell potency and the ability to contribute to chimeric organisms. Reproduction (2013) 0.80
Nanoinjection: pronuclear DNA delivery using a charged lance. Transgenic Res (2012) 0.78
Transgene delivery via intracellular electroporetic nanoinjection. Transgenic Res (2013) 0.78
Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases. World J Hepatol (2015) 0.77
Contribution of Mouse Embryonic Stem Cells and Induced Pluripotent Stem Cells to Chimeras through Injection and Coculture of Embryos. Stem Cells Int (2014) 0.76